Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRETT ASHLEY BENNETT

Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology

NPI
1538471842
CMS profile
205419
Location
JACKSON, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,963.74

117 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,963.74 117

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRETT ASHLEY BENNETT

NPI 1538471842 · CMS profile ID 205419

Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology

JACKSON, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538471842?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRETT ASHLEY BENNETT, NPI 1538471842, CMS profile ID 205419. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538471842?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BRETT ASHLEY BENNETT, NPI 1538471842, CMS profile ID 205419. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538471842?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BRETT ASHLEY BENNETT, NPI 1538471842, CMS profile ID 205419, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1538471842?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

117 matching records · $2,963.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 117 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 117.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $3.3007/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825188273 CMS
ABIOMED $22.5407/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848772155 CMS
Novartis Pharmaceuticals Corporation $20.1207/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812606511 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.4607/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763402596 CMS
ABIOMED $71.1207/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848772129 CMS
ABIOMED $10.9307/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848772137 CMS
AstraZeneca Pharmaceuticals LP $11.0407/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830005747 CMS
BOSTON SCIENTIFIC CORPORATION $22.8206/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777718563 CMS
BOSTON SCIENTIFIC CORPORATION $85.2806/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777718561 CMS
AstraZeneca Pharmaceuticals LP $18.0206/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830088901 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.5806/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763402598 CMS
BOSTON SCIENTIFIC CORPORATION $94.7206/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777718565 CMS
Novartis Pharmaceuticals Corporation $21.3806/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812606509 CMS
Amgen Inc. $14.7106/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825188269 CMS
ABIOMED $50.2506/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848772121 CMS
ABIOMED $19.3306/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848772119 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.3006/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763402600 CMS
Merck Sharp & Dohme Corporation $13.3606/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848336467 CMS
Amgen Inc. $3.3006/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825188265 CMS
Avinger Inc. $23.5206/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 770480880 CMS
Novartis Pharmaceuticals Corporation $20.9806/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812606505 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $12.7205/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768802390 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.4405/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763402602 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.8005/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763402604 CMS
Novartis Pharmaceuticals Corporation $14.4205/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812606507 CMS
ABIOMED $58.8205/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848772123 CMS
Amgen Inc. $4.4605/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825188261 CMS
BOSTON SCIENTIFIC CORPORATION $52.4505/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777623739 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.8305/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763402606 CMS
Novartis Pharmaceuticals Corporation $20.8005/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812606503 CMS
Merck Sharp & Dohme Corporation $15.4105/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848604495 CMS
ABIOMED $26.7205/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848772093 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.0704/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763402608 CMS
BOSTON SCIENTIFIC CORPORATION $105.4804/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777702573 CMS
Kiniksa Pharmaceuticals, Ltd. $11.2504/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852919269 CMS
Novartis Pharmaceuticals Corporation $18.3204/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812606501 CMS
BOSTON SCIENTIFIC CORPORATION $41.9904/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777702571 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.8104/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763402610 CMS
Amgen Inc. $3.3004/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825188257 CMS
Merck Sharp & Dohme Corporation $14.3404/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848327209 CMS
Amgen Inc. $12.2904/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825188253 CMS
Novartis Pharmaceuticals Corporation $20.2404/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812606499 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.2203/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763402612 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $13.3203/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768802388 CMS
ABIOMED $39.6603/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848772111 CMS
Novartis Pharmaceuticals Corporation $18.2103/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812606497 CMS
BOSTON SCIENTIFIC CORPORATION $29.2603/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777761273 CMS
ABIOMED $16.8003/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848772109 CMS
Amgen Inc. $3.3003/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825188245 CMS
Esperion Therapeutics, Inc. $13.8803/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838245985 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $13,235.78 175
PY2020 $2,603.74 78
PY2021 $2,963.74 117
PY2022 $18,250.11 120
PY2023 $36,330.05 138
PY2024 $11,624.44 107
PY2025 $40,554.53 172

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $34,807.85 81
PY2024 Principal investigator $41,007.59 17
PY2023 Principal investigator $75,545.05 30
PY2022 Principal investigator $84,017.33 34
PY2021 Principal investigator $39,939.04 27
PY2020 Principal investigator $87,073.34 27
PY2019 Principal investigator $72,965.50 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693597
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693599
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693593
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693595
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 10/27/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693601
Principal investigator 1 Medtronic, Inc. $500.00 10/10/2025 Non-covered Recipient Entity
Jackson Heart Clinic P.A.
PSR-Coronary No dispute reported 06/30/2026 1192324021
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693589
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693591
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 09/24/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693583
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/24/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693585
Principal investigator 1 Boehringer Ingelheim International GmbH $3.76 09/24/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693587
Principal investigator 1 Medtronic, Inc. $500.00 09/19/2025 Non-covered Recipient Entity
Jackson Heart Clinic P.A.
PSR-Coronary No dispute reported 06/30/2026 1192324019
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693575
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693577
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693571
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693573
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693579
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693581
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 06/24/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693567
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 06/24/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693569
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693561
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693563
Principal investigator 1 Boehringer Ingelheim International GmbH $38.00 05/08/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693605
Principal investigator 1 Boehringer Ingelheim International GmbH $43.24 05/08/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693609
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 05/08/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693619
Principal investigator 1 Boehringer Ingelheim International GmbH $4.64 05/08/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693621
Principal investigator 1 Boehringer Ingelheim International GmbH $40.45 05/08/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693629
Principal investigator 1 Boehringer Ingelheim International GmbH $62.39 05/08/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693631
Principal investigator 1 Boehringer Ingelheim International GmbH $40.45 05/08/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693633
Principal investigator 1 Boehringer Ingelheim International GmbH $62.39 05/08/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693635
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693541
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693543
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693545
Principal investigator 1 Boehringer Ingelheim International GmbH $780.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693547
Principal investigator 1 Boehringer Ingelheim International GmbH $16,300.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693549
Principal investigator 1 Boehringer Ingelheim International GmbH $1,800.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693551
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693553
Principal investigator 1 Boehringer Ingelheim International GmbH $250.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693555
Principal investigator 1 Boehringer Ingelheim International GmbH $28.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693603
Principal investigator 1 Boehringer Ingelheim International GmbH $4.59 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693607
Principal investigator 1 Boehringer Ingelheim International GmbH $21.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693611
Principal investigator 1 Boehringer Ingelheim International GmbH $14.84 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693613
Principal investigator 1 Boehringer Ingelheim International GmbH $4.70 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693615
Principal investigator 1 Boehringer Ingelheim International GmbH $33.56 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693617
Principal investigator 1 Boehringer Ingelheim International GmbH $60.06 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693623
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693625
Principal investigator 1 Boehringer Ingelheim International GmbH $124.99 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693627
Principal investigator 1 Boehringer Ingelheim International GmbH $123.97 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693639
Principal investigator 1 Boehringer Ingelheim International GmbH $57.19 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693641
Principal investigator 1 Boehringer Ingelheim International GmbH $38.36 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693643
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693645
Principal investigator 1 Boehringer Ingelheim International GmbH $60.06 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693647
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693649
Principal investigator 1 Boehringer Ingelheim International GmbH $124.99 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693651
Principal investigator 1 Boehringer Ingelheim International GmbH $303.60 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693653
Principal investigator 1 Boehringer Ingelheim International GmbH $263.22 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693655
Principal investigator 1 Boehringer Ingelheim International GmbH $123.97 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693657
Principal investigator 1 Boehringer Ingelheim International GmbH $57.19 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693659
Principal investigator 1 Boehringer Ingelheim International GmbH $38.36 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693661
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 05/07/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693663
Principal investigator 1 Medtronic, Inc. $256.00 05/02/2025 Non-covered Recipient Entity
Jackson Heart Clinic P.A.
PSR-Coronary No dispute reported 06/30/2026 1192324017
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693557
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693559
Principal investigator 1 Boehringer Ingelheim International GmbH $743.71 05/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220693637
Principal investigator 1 Boehringer Ingelheim International GmbH $1.55 04/23/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693565
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693537
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693539
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 03/25/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693529
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 03/25/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693531
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 03/25/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693533
Principal investigator 1 Boehringer Ingelheim International GmbH $11.28 03/25/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693535
Principal investigator 1 Medtronic, Inc. $300.00 03/14/2025 Non-covered Recipient Entity
Jackson Heart Clinic P.A.
PSR-Coronary No dispute reported 06/30/2026 1192324015
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693521
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693523
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 02/25/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693527
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693517
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693519
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693525
Principal investigator 1 Medtronic, Inc. $5,722.00 01/17/2025 Non-covered Recipient Entity
Jackson Heart Clinic P.A.
PSR-Coronary No dispute reported 06/30/2026 1192324013
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693513
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Jackson Heart Clinic PA Admin Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220693515